Genmab A/S (OTCMKTS:GNMSF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, Zacks.com reports. The firm presently has a $202.00 price objective on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 13.59% from the stock’s current price.
According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “
Genmab A/S stock opened at $177.84 on Wednesday. The company has a 50 day moving average of $177.76. The stock has a market cap of $10.90 billion, a P/E ratio of 55.40 and a beta of 0.16. Genmab A/S has a 1 year low of $119.10 and a 1 year high of $186.30.
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Recommended Story: What are benefits of a growth and income fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.